ストックスクリーナーアプリを入手
15.67
2.75%
0.42
前日終値:
$15.25
開ける：
$15.315
24時間の取引高:
1.25M
Relative Volume:
1.06
時価総額：
$1.74B
収益：
$-665.00K
当期純損益:
$-150.11M
株価収益率:
-10.40
EPS:
-1.5071
ネットキャッシュフロー:
$-124.53M
1週間 パフォーマンス:
+12.65%
1か月 パフォーマンス:
+21.85%
6か月 パフォーマンス:
+31.46%
1年 パフォーマンス:
+207.25%
1日の値動き範囲:
$15.31
$16.20
1週間の範囲:
$13.84
$16.20
52週間の値動き範囲:
$4.80
$18.61
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
名前
Amylyx Pharmaceuticals Inc
セクター
電話
617-682-0917
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
15.67 | 1.74B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-03 | 開始されました | Stifel | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Guggenheim | Buy |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-05-30 | 開始されました | TD Cowen | Buy |
| 2025-04-07 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-11-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-03-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-24 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-01-05 | 開始されました | BofA Securities | Buy |
| 2022-05-25 | 開始されました | Citigroup | Buy |
| 2022-04-01 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amylyx Pharmaceuticals eyes Q3 phase 3 Avexitide readout as PBH launch plans take shape - MSN
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape - Yahoo Finance
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 - BioSpace
Amylyx (NASDAQ: AMLX) director receives 24,372 stock options grant - Stock Titan
Amylyx (AMLX) director Karen Firestone receives 24,372 stock options grant - Stock Titan
Amylyx (NASDAQ: AMLX) director receives 24,372-share stock option grant - Stock Titan
Amylyx (NASDAQ: AMLX) director awarded 24,372 stock options at $14.31 strike - Stock Titan
Amylyx (AMLX) director Paul Fonteyne receives grant of 24,372 stock options - Stock Titan
Claim your share of the $6.5M Amylyx Pharmaceuticals securities class action settlement - Claim Depot
Post-bariatric hypoglycemia toll, avexitide trial design at ENDO 2026 - Stock Titan
H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights - Investing.com
Amylyx earnings on deck ahead of pivotal avexitide trial data By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals eyes phase 3 AVEXITIDE readout as 2027 launch comes into focus - MSN
Amylyx Pharmaceuticals (NASDAQ: AMLX) investors approve directors, auditor and say-on-pay - Stock Titan
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound - Yahoo Finance
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Amylyx Pharmaceuticals (AMLX) Gains 3.36% as Shares Approach ResistanceWatchlist Stock Ideas - thelegaladvocate.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX) - The Globe and Mail
Amylyx director Karen Firestone purchases $51,338 of common stock. By Investing.com - Investing.com Nigeria
Amylyx director Karen Firestone purchases $51,338 of common stock. - Investing.com
Director Karen Firestone adds Amylyx Pharmaceuticals (AMLX) shares - Stock Titan
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Pharmaceuticals (AMLX) Slips 2.5% as Biotech Sector Faces Renewed ScrutinyAAII Bullish - thelegaladvocate.com
Amylyx Stock: Why the Full Pipeline Story Matters - MarketBeat
Guggenheim Initiates Coverage of Amylyx Pharmaceuticals (AMLX) with Buy Recommendation - MSN
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer FRATES JAMES M - Moomoo
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress - Insider Monkey
Amylyx Pharmaceuticals, Inc.Common Stock (NQ: AMLX - FinancialContent
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation - BioSpace
Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal - Yahoo Finance
Number of shareholders of Amylyx Pharmaceuticals, Inc. – BOATS:AMLX - TradingView
Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A - Stock Titan
Amylyx publishes phase 2 Wolfram syndrome trial results - Investing.com
Amylyx Pharmaceuticals Inc (AMLX) 財務データ
収益
当期純利益
現金流量
EPS
11.23%
0.45%
大文字化:
|
ボリューム (24 時間):